Evidence map›Paper›PMID 36386359›Full record

ArticleFrontiers in cardiovascular medicine2022

The relationship between atherosclerotic disease and relapse during ATD treatment.

Xinxin Zhu, Yaguang Zhang, Xiaoyu Zhao, Xiaona Zhang, Zixuan Ru, Yanmeizhi Wu, Xu Yang, Boyu Hou, Hong Qiao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xinxin ZhuDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Yaguang ZhangDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiaoyu ZhaoDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiaona ZhangDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zixuan RuDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Yanmeizhi WuDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Xu YangDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Boyu HouDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Hong QiaoDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Harbin Medical University · CNSecond Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clinical relapse is a potential risk for traditional antithyroid drug (ATD) treatment in hyperthyroid patients. Evidence suggests that atherosclerotic disease is closely associated with hyperthyroidism, while the relationship between atherosclerosis and relapse remains unclear. Methods: Two hundred and twenty-five patients with GD who underwent ATD as their first treatment were studied; 88 and 137 patients were categorized as drug reduction relapse and drug reduction remission, respectively. Logistic regression was used to analyze risk factors of drug reduction relapse in patients with GD. Results: During a median of 48 months followed up 88 patients who relapsed. According to multivariate analyses, atherosclerosis related diseases, FT4, goiter, and anxiety rating scores are independent risk factors for drug reduction. According to K-M survival analysis, patients with atherosclerosis related diseases, FT4 > 18.82 pmol/L, anxiety rating scores > 23, and gradation of goiter ≥ Grade II had a higher risk of relapse than those with lower levels. ROC analysis shown atherosclerosis related diseases significantly improved the predictive accuracy of relapse. Conclusions: Atherosclerotic disease is closely related to the relapse of hyperthyroidism, ATD treatment in hyperthyroid patients with atherosclerosis should be given more attention.

Indexed as

antithyroid drugatherosclerotic diseasedrug reductionGraves' diseaserisk factors

Identifiers

PMID36386359
PMCPMC9650150
OpenAlexW4307703894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.